ArticleCureus2026
The Systemic Immune Signature of Cholesteatoma: A Comprehensive Cross-Sectional Analysis of Hematological Markers and Clinical Staging.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholesteatoma is an inflammatory disease of the middle ear, which is characterized by hearing loss, bony destruction, and increased potential for complications. The inflammation plays a major role in the pathogenesis of disease; however, the relationship between systemic haematological inflammatory markers and disease severity remains inadequately understood. This study attempts to evaluate this association between conventional and novel inflammatory markers and the staging of cholesteatoma.
methodsThis study is a prospective cross-sectional analytical study, conducted at a tertiary care center in Central India over 18 months. Seventy-two patients with chronic otitis media (COM) squamosal disease undergoing tympanomastoid surgery and having confirmed or suspected cholesteatoma were included. The patients were further classified as per the European Academy of Otology and Neurotology/Japan Otological Society (EAONO/JOS 2017) staging system. The blood examinations done preoperatively were complete blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). The neutrophil-to-lymphocyte ratio (NLR) and Systemic Immune-Inflammation Index (SII) from complete blood count were calculated. Comparisons across the various disease stages were performed using the Kruskal-Wallis test, and correlations with disease stage were assessed using Spearman's rank correlation.
resultsThe age range was 6-55 years, with a mean age of 25.36 ± 11.56 years. There was no marked gender predominance observed in the study. As per staging, stage II disease was the most common presentation seen in 40 (55.6%) cases, followed by stage III in 26 (36.1%) cases. The median values of all inflammatory markers increased progressively with advancing stage of cholesteatoma. The Systemic Immune-Inflammation Index progressively increased from 286.5 (interquartile range (IQR): 276.75-424.00) in stage I to 1304.0 (IQR: 1163.0-1445.0) in stage IV. Although the neutrophil-to-lymphocyte ratio, erythrocyte sedimentation rate, and C-reactive protein showed upward trends with disease severity, interstage differences were not statistically significant. Spearman's rank correlation coefficients (ρ) between inflammatory markers for the Systemic Immune-Inflammation Index and erythrocyte sedimentation ratio demonstrated statistically significant positive correlations with advancing disease stage.
conclusionThe systemic inflammatory burden increases with advancing stage of cholesteatomatous otitis media. However, among the evaluated biomarkers, the Systemic Immune-Inflammation Index demonstrated the strongest and most significant association with disease severity. Hence, it has a potential utility as an inexpensive, readily available adjunctive marker for preoperative assessment and risk estimation in patients with cholesteatomatous chronic otitis media.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.